BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE

Biontech Se Sponsored Adr (($BNTX)) has held its Q4 earnings call. Read on for the main highlights of the call. BioNTech’s latest earnings call str...

BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID

BioNTech SE ( ($BNTX) ) has issued an announcement. BioNTech SE disclosed in an April 2, 2026 Form 6-K that it has convened its 2026 Annual General...

BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX) and Biomea Fusion (BMEA). BioNT...

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)

BioNTech SE ( ($BNTX) ) has issued an announcement. BioNTech SE, a leading immunotherapy developer, is expanding its late-stage lung cancer pipelin...

BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC – Research Report) and BioNTech SE (B...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Evercore ISI analyst Cory Kasimov maintained a Buy rating on BioNTech SE today and set a price target of $130.00. Kasimov covers the Healthcare sec...

Evercore ISI Remains a Buy on BioNTech SE (BNTX)

Goldman Sachs analyst Asad Haider maintained a Buy rating on BioNTech SE today and set a price target of $132.00. Haider covers the Healthcare sect...

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE today and set a price target of $171.00. Newman covers the Healthcare ...

Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Senseonics Holdings (SENS – Research Report) and Bio...

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and BioNTech SE (BNTX)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE today and set a price target of $140.00. Papadakis covers the Healt...

Deutsche Bank  Keeps Their Buy Rating on BioNTech SE (BNTX)

An update from BioNTech SE ( ($BNTX) ) is now available. On March 10, 2026, BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will es...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BNTX	$92.16	+2.83%	328.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BNTX	$92.16	+2.8%	328.05K
3
4
5
6

BNTX

BNTX

No Data Available

Get BioNTech SE Data in Excel

Get BioNTech SE Data in Excel